<DOC>
	<DOCNO>NCT02181686</DOCNO>
	<brief_summary>The objective study confirm safety efficacy new Sentus OTW QP LV lead Iperia ICD family . The study focus safety efficacy QP device system .</brief_summary>
	<brief_title>Iperia/Sentus QP Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<criteria>Patient able understand nature study provide write informed consent . Patient meet standard indication CRTD ( Sentus QP group ) ICD therapy . Patient able willing complete plan followup visit investigational site . Patient accept Home Monitoring® concept . Age ≥ 18 year . Sentus QP group : Patient candidate new ( de novo ) implant upgrade exist ICD pacemaker utilize BIOTRONIK Sentus QP lead Patient standard contraindication CRTD ( Sentus QP group ) ICD therapy . Sentus QP group : Currently implant endocardial epicardial LV lead prior attempt place LV lead . Sentus QP group : Cardiac surgery procedure ( coronary bypass graft , valve surgery , ablation ) plan occur within 3 month implantation . Patient expect receive ventricular assist device heart transplantation within next 3 month . Patient pregnant breastfeeding . Life expectancy le 3 month Participating another cardiac clinical investigation active treatment arm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Iperia ICD family</keyword>
	<keyword>Sentus QP leave ventricular lead</keyword>
	<keyword>Quadripolar CRT-D system</keyword>
</DOC>